On the other hand, aberrant signaling via IL‐17 promotes pathogenesis of several autoimmune disorders, such as psoriasis, atopic dermatitis, rheumatoid arthritis, or multiple sclerosis (Brembilla et al, 2018) and therapeutic antibodies blocking IL‐17 or its receptor have been successfully used in clinic to treat severe plaque psoriasis (Bilal et al, 2018; Hawkes et al, 2018). Here, IL17A is linked to atopic eczema.